Table 2.
Association between clinicopathological parameters and TB or PDC low/high status in gastric adenocarcinoma (pT: Primary tumor extent, pN: Regional lymph node metastasis, pM: Distant metastasis, UICC: Union for International Cancer Control, n.s.: statistically non-significant; Statistically significant p values are displayed in bold).
| Parameter | Tumor Budding | Poorly Differentiated Cluster | |||||
|---|---|---|---|---|---|---|---|
| Low (0 + 1 + 2) | High (3) | p | Low (0 + 1 + 2) | High (3) | p | ||
| Number of patients (n) | n | 62 (21.38%) | 228 (78.62%) | - | 56 | 234 | - |
| Age (mean, range) | mean (years), range | 68.4 (49–87) | 65.5 (34–89) | n.s. | 66.446 | 66.051 | n.s. |
| Sex | female | 23 (37.1%) | 84 (36.8%) | 1 | 18 (32.1%) | 89 (38.0%) | n.s. |
| male | 39 (62.9%) | 144 (63.2%) | 38 (67.9%) | 145 (62.0%) | |||
| Extent of gastrectomy | total | 34 (54.8%) | 150 (65.8%) | n.s. | 35 (62.5%) | 149 (63.7%) | n.s. |
| subtotal | 28 (45.2%) | 78 (34.2%) | 21 (37.5%) | 85 (36.3%) | |||
| Location | cardia | 17 (27.4%) | 81 (35.5%) | n.s. | 19 (33.9%) | 79 (33.8%) | n.s. |
| distal | 45 (75.6%) | 147 (64.5%) | 37 (66.1%) | 155 (66.2%) | |||
| Lauren classification | intestinal | 48 (77.4%) | 111 (48.7%) | 0.0003 | 41 (73.2%) | 118 (50.4%) | 0.0086 |
| diffuse | 11 (17.7%) | 96 (42.1%) | 13 (23.2%) | 94 (40.2%) | |||
| mixed | 3 (4.8%) | 21 (9.2%) | 2 (3.6%) | 22 (9.4%) | |||
| Resection margin | R0 | 55 (88.7%) | 167 (73.2%) | 0.0174 | 49 (87.5%) | 173 (73.9%) | 0.0480 |
| R1 | 7 (11.3%) | 61 (26.8%) | 7 (12.5%) | 61 (26.1%) | |||
| Perineural invasion | present | 10 (16.1%) | 71 (31.1%) | 0.0295 | 9 (16.1%) | 72 (30.8%) | 0.0417 |
| absent | 52 (83.9%) | 157 (68.9%) | 47 (83.9%) | 162 (69.2%) | |||
| Lymphovascular invasion | present | 28 (45.2%) | 151 (66.2%) | 0.0032 | 28 (50.0%) | 151 (64.5%) | 0.0481 |
| absent | 34 (54.8%) | 77 (33.8%) | 28 (50.0%) | 83 (35.5%) | |||
| pT | I–II | 22 (35.5%) | 25 (11.0%) | <0.0001 | 38 (67.9%) | 29 (12.4%) | <0.0001 |
| III–IV | 40 (64.5%) | 203 (89.0%) | 18 (32.1%) | 205 (87.4%) | |||
| Tumor differentiation | well | 5 (8.1%) | 1 (0.4%) | <0.0001 | 4 (7.1%) | 2 (0.9%) | <0.0001 |
| moderate | 30 (48.4%) | 62 (27.2%) | 30 (53.6%) | 62 (26.5%) | |||
| poor | 27 (43.5%) | 165 (72.4%) | 22 (39.3%) | 170 (72.6%) | |||
| UICC Stage | I–II | 42 (67.7%) | 80 (35.1%) | <0.0001 | 27 (48.2%) | 95 (40.6%) | n.s. |
| III–IV | 20 (32.3%) | 148 (64.9%) | 29 (51.8%) | 139 (59.4%) | |||
| Lymph node metastasis (pN) | present | 31 (50%) | 179 (78.5%) | <0.0001 | 36 (64.3%) | 174 (74.4%) | n.s. |
| absent | 31 (50%) | 49 (21.5%) | 20 (35.7%) | 60 (25.6%) | |||
| Distant metastasis (pM) | M0 | 61 (98.4%) | 212 (93.0%) | n.s. | 52 (92.9%) | 221 (94.4%) | n.s. |
| M1 | 1 (1.6%) | 16 (7.0%) | 4 (7.1%) | 13 (5.6%) | |||